DDInter500 DDInter1657
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Denosumab {u} may lead to a major life threatening interaction when taken with {v} Etelcalcetide
Denosumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Denosumab may lead to a major life threatening interaction when taken with Etelcalcetide
Denosumab may lead to a major life threatening interaction when taken with Cladribine